2015 MEDICHEM Minisymposium "Prevention and Management of Asbestos-Related Diseases", June 4, 2-4 p.m. in Seoul, Korea

More than 100,000 people worldwide die each year from mesothelioma, lung cancer and asbestosis.

Two million tons of asbestos are still produced by five countries. Dozens of millions of tons of asbestos still prevail in the existing buildings and industrial facilities. Although the epidemic of asbestos-related diseases has plateaued or is expected to plateau in the industrialized world, little is known about epidemic in developing countries. It is obvious that increased asbestos use by these countries will result in an increase in asbestos-related diseases in future.

Asbestos-related diseases constitute a unique type of morbidity in several aspects: Cumulative dose with poor or no elimination and clearance, long latency period between exposure and disease outcome, several types of morbidity with different shapes of dose-response, for example, asbestosis, pleural plaques and numerous types of cancers. In all these aspects, early diagnosis is of the utmost value, but simultaneously, challenging.

Globally, the health consequences of the worldwide use of asbestos are starting to be increasingly visible in countries that have sufficiently efficient systems for prevention, diagnosis, notification, registration and compensation.

The talks in this MEDICHEM Minisymposium give an example how a developed country dealt with the challenges of Prevention and Management of Asbestos-Related Diseases.

As an introduction, the Chairman of MEDICHEM will introduce the history and expertise of MEDICHEM.

Chair : Maren Beth-Hübner (Germany), Murray Coombs (South Africa)
Responsible Person : Maren Beth-Hübner (Germany)
1 [SS-0130]
Legal definition of occupational diseases in Germany is essential for the understanding of the compensation of lung cancers due to asbestos
Hans Drexler
Germany
Abstract
Full Lecture
2 [SS-0132]
Development of asbestos related diseases in Germany and case-related retrospective fibre dose evaluation
Markus Mattenklott
Germany
Abstract
3 [SS-0133]
Biomarkers for early detection of asbestos-associated cancers
Georg Johnen
Germany
Abstract
Full Lecture
4 [SS-0134]
Detection rates of lung cancer and asbestos related findings in former asbestos workers in the power industry - Update and follow-up results of the Aachen asbestos surveillance program (ASPA)
Thomas Kraus
Germany
Abstract
5 [SS-0135]
Early detection of asbestos-related lung cancer by low-dose multislice-CT (low-dose MSCT)
Volker Harth
Germany
Abstract
Full Lecture
This site is designed and supported by Shoreland, Inc., publisher of Shoreland Travax®.